Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Bennett

Showing results (1-10 of 175) with videos related to

Pageof 18
Sort By:
Novartis Foundation Symposium|January 31, 2004
Gene therapy for Leber congenital amaurosisJean Bennett
Retina (Philadelphia, Pa.)|December 24, 2005
Strategies for delivery of rod-derived cone viability factorJean Bennett
The New England Journal of Medicine|April 13, 2007
Retinal progenitor cells--timing is everythingJean Bennett
Human Gene Therapy|February 4, 2006
Commentary: an aye for eye gene therapyJean Bennett
The New England Journal of Medicine|December 19, 2009
Gene therapy for color blindnessJean Bennett
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 11, 2017
Taking Stock of Retinal Gene Therapy: Looking Back and Moving ForwardJean Bennett
JAMA Ophthalmology|September 2, 2016
Institutional Conflict of InterestJean Bennett
Human Gene Therapy|August 20, 2014
My career path for developing gene therapy for blinding diseases: the importance of mentors, collaborators, and opportunitiesJean Bennett
Cold Spring Harbor Perspectives in Medicine|November 14, 2022
Overview of Retinal Gene Therapy: Current Status and Future ChallengesJean Bennett
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 2, 2011
Switching on the lights: the use of optogenetics to advance retinal gene therapyTherese Cronin, Jean Bennett
Pageof 18

Showing results (1-10 of 175) with videos related to

Sort By:
Pageof 18
Novartis Foundation Symposium|January 31, 2004
Gene therapy for Leber congenital amaurosisJean Bennett
Retina (Philadelphia, Pa.)|December 24, 2005
Strategies for delivery of rod-derived cone viability factorJean Bennett
The New England Journal of Medicine|April 13, 2007
Retinal progenitor cells--timing is everythingJean Bennett
Human Gene Therapy|February 4, 2006
Commentary: an aye for eye gene therapyJean Bennett
The New England Journal of Medicine|December 19, 2009
Gene therapy for color blindnessJean Bennett
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 11, 2017
Taking Stock of Retinal Gene Therapy: Looking Back and Moving ForwardJean Bennett
JAMA Ophthalmology|September 2, 2016
Institutional Conflict of InterestJean Bennett
Human Gene Therapy|August 20, 2014
My career path for developing gene therapy for blinding diseases: the importance of mentors, collaborators, and opportunitiesJean Bennett
Cold Spring Harbor Perspectives in Medicine|November 14, 2022
Overview of Retinal Gene Therapy: Current Status and Future ChallengesJean Bennett
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 2, 2011
Switching on the lights: the use of optogenetics to advance retinal gene therapyTherese Cronin, Jean Bennett
Pageof 18